povorcitinib - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

TVS Motor Company (TVSMOTOR) enters Africa premium motorcycle market with Apache RTR 310 launch in Morocco

TVS Motor launches Apache RTR 310 in Morocco, making its first move into Africa’s premium motorcycle segment

Representative image of resistant hypertension screening and cortisol-related disease, illustrating Corcept Therapeutics’ MOMENTUM trial findings on hypercortisolism prevalence in difficult-to-treat blood pressure patients.

Corcept Therapeutics (NASDAQ: CORT) puts resistant hypertension in the cortisol spotlight with new MOMENTUM trial data

Representative image of the United States Capitol as the Department of Homeland Security shutdown fight deepens, with the House passing a 60-day funding bill that Senate Democrats say they will block.

DHS shutdown set to drag on as House sends Senate a bill Democrats vow to block

Representative image of oral hidradenitis suppurativa treatment research as Incyte Corporation reports positive 54-week povorcitinib Phase 3 data, highlighting the race to expand HS therapy options.

Incyte (NASDAQ: INCY) moves closer to an hidradenitis suppurativa launch as 54-week povorcitinib data hold up

Representative image of oral hidradenitis suppurativa treatment research as Incyte Corporation reports positive 54-week povorcitinib Phase 3 data, highlighting the race to expand HS therapy options.

Read More

Pharma Industry News

Incyte (NASDAQ: INCY) moves closer to an hidradenitis suppurativa launch as 54-week povorcitinib data hold up

Incyte Corporation’s new 54-week povorcitinib data could reshape hidradenitis suppurativa treatment. Read what it means for INCY now.

byPallavi Madhiraju

March 29, 2026

web analytics